The overall survival (OS) is less to 6 month for the advanced stage of CM patients, and improved since 2011, with the successful treatment of CM with BRAF inhibitor, anti-CTLA-4 therapy, and anti-PD-1 therapy, with a favorable OS result of about 40% 5-year survival rate 8-11. Here, BRAF is linked to cutaneous mastocytosis.